For all the high-flying claims for AI in drug discovery, Leash Bio has started with a more grounded approach — literally.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2023 Earnings Call Transcript
Recursion to Host Public L(earnings) Call on February 27
Altitude Lab Startups Raise Over $120M in Capital
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
Recursion Pharma spikes after licensing deal with Bayer
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
Bayer and Recursion focus research collaboration on Oncology
Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world™s...
SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference on Machine Learning (ICML). Valence Labs will serve as a machine learning research laboratory focused on developing the next generation of cutting-edge methods and models for drug discovery and consists of the emerging ML research teams at Recursion and the team at Valence Discovery, which Recursion recently acquired.